Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
MedComm - Oncology is Scopus-indexed (Q2, CiteScore 5.3), WoS ESCI, DOAJ. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 2769-6448Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry, Genetics and Molecular Biology (miscellaneous) | 39 / 144 | 73rd | Q2 |
| Oncology | 145 / 428 | 66th | Q2 |
| Cancer Research | 119 / 233 | 49th | Q3 |
| Cell Biology | 164 / 289 | 43rd | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2022–present, best quartile Q2, CiteScore 5.3.
MedComm - Oncology is Q2 in Biochemistry, Genetics and Molecular Biology (miscellaneous) (rank 39 of 144), Q2 in Oncology (rank 145 of 428) and Q3 in Cancer Research (rank 119 of 233), by CiteScore 2025. It is ranked in 4 subject areas in all.
MedComm - Oncology is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.3, which places it in quartile Q2 at the 73rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.502, quartile Q1, with an H-index of 14.
No article processing charge is recorded for it (source: OpenAlex). Confirm on the journal's own website, since some journals charge for extras such as colour figures.
MedComm - Oncology is published by John Wiley and Sons Inc. Its ISSN is 2769-6448.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
MedComm - Oncology has an h-index of 20 and a 2-year mean of 5.36 citations per paper (OpenAlex). Its Scopus CiteScore is 5.3, quartile Q2. On 2-year citations it ranks #18 of 141 Scopus journals in Biochemistry, Genetics and Molecular Biology (miscellaneous).
MedComm - Oncology published 51 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2024–2026), authors are most often from China (87.3%), United States (3.8%) and Australia (2.3%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.